Onconox Inc.

Onconox Inc. is a pioneering biotechnology research company dedicated to developing precision, low-burden therapies for oncology and neurodegenerative diseases. Headquartered in Monmouth Junction, New Jersey, Onconox Inc. focuses on reformulating validated small molecules and delivering them directly to the site of disease through advanced inhaled, intranasal, and direct-to-tumor technologies. This innovative approach maximizes therapeutic impact while reducing systemic toxicity, improving adherence, and accelerating clinical development.

With a mission to deliver patient-centered therapies that improve survival and quality of life, Onconox Inc. is committed to transforming known molecules to solve medicine's hardest challenges. The company's lead asset, OCN001, is being advanced as a first-in-class inhaled therapy intended to enhance the effectiveness of radiotherapy in non-small cell lung cancer. By delivering therapy directly to the lungs, OCN001 aims to improve tumor control and reduce treatment burden. The company’s primary address is 11 Deerpark Dr, Monmouth Junction, New Jersey 08852, US.

Onconox Inc.’s platform supports a robust pipeline of inhaled, intranasal, and direct-to-tumor programs targeting lung cancer, glioblastoma, solid tumors, and neurodegeneration. Each program leverages shared formulation expertise, device-enabled delivery, and expanding intellectual property to create a scalable portfolio with multiple shots on goal. Onconox Inc. is poised to become a leader in precision-delivered therapeutics. We invite the manager of Onconox Inc. to create a customized and exclusive company showcase and product listing on our platform.